These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 17209012)

  • 1. HIV-susceptible transgenic rats allow rapid preclinical testing of antiviral compounds targeting virus entry or reverse transcription.
    Goffinet C; Allespach I; Keppler OT
    Proc Natl Acad Sci U S A; 2007 Jan; 104(3):1015-20. PubMed ID: 17209012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary T-cells from human CD4/CCR5-transgenic rats support all early steps of HIV-1 replication including integration, but display impaired viral gene expression.
    Goffinet C; Michel N; Allespach I; Tervo HM; Hermann V; Kräusslich HG; Greene WC; Keppler OT
    Retrovirology; 2007 Jul; 4():53. PubMed ID: 17655755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults.
    Lalezari JP; DeJesus E; Northfelt DW; Richmond G; Wolfe P; Haubrich R; Henry D; Powderly W; Becker S; Thompson M; Valentine F; Wright D; Carlson M; Riddler S; Haas FF; DeMasi R; Sista PR; Salgo M; Delehanty J
    Antivir Ther; 2003 Aug; 8(4):279-87. PubMed ID: 14518696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progress toward a human CD4/CCR5 transgenic rat model for de novo infection by human immunodeficiency virus type 1.
    Keppler OT; Welte FJ; Ngo TA; Chin PS; Patton KS; Tsou CL; Abbey NW; Sharkey ME; Grant RM; You Y; Scarborough JD; Ellmeier W; Littman DR; Stevenson M; Charo IF; Herndier BG; Speck RF; Goldsmith MA
    J Exp Med; 2002 Mar; 195(6):719-36. PubMed ID: 11901198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relief of preintegration inhibition and characterization of additional blocks for HIV replication in primary mouse T cells.
    Zhang JX; Diehl GE; Littman DR
    PLoS One; 2008 Apr; 3(4):e2035. PubMed ID: 18446227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is there a future for antiviral fusion inhibitors?
    Berkhout B; Eggink D; Sanders RW
    Curr Opin Virol; 2012 Feb; 2(1):50-9. PubMed ID: 22440966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased CD4 and CCR5 expression and human immunodeficiency virus type 1 entry in CD40 ligand-stimulated macrophages.
    Bergamini A; Bolacchi F; Pesce CD; Carbone M; Cepparulo M; Demin F; Rocchi G
    J Infect Dis; 2002 Jun; 185(11):1567-77. PubMed ID: 12023762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The V1-V3 region of a brain-derived HIV-1 envelope glycoprotein determines macrophage tropism, low CD4 dependence, increased fusogenicity and altered sensitivity to entry inhibitors.
    Rossi F; Querido B; Nimmagadda M; Cocklin S; Navas-Martín S; Martín-García J
    Retrovirology; 2008 Oct; 5():89. PubMed ID: 18837996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting CCR5 as a Component of an HIV-1 Therapeutic Strategy.
    Mohamed H; Gurrola T; Berman R; Collins M; Sariyer IK; Nonnemacher MR; Wigdahl B
    Front Immunol; 2021; 12():816515. PubMed ID: 35126374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protein kinase C-delta regulates HIV-1 replication at an early post-entry step in macrophages.
    Contreras X; Mzoughi O; Gaston F; Peterlin MB; Bahraoui E
    Retrovirology; 2012 May; 9():37. PubMed ID: 22554282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Entry inhibitors and their use in the treatment of HIV-1 infection.
    Haqqani AA; Tilton JC
    Antiviral Res; 2013 May; 98(2):158-70. PubMed ID: 23541872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targets for inhibition of HIV replication: entry, enzyme action, release and maturation.
    Sierra-Aragón S; Walter H
    Intervirology; 2012; 55(2):84-97. PubMed ID: 22286875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Susceptibility of rat-derived cells to replication by human immunodeficiency virus type 1.
    Keppler OT; Yonemoto W; Welte FJ; Patton KS; Iacovides D; Atchison RE; Ngo T; Hirschberg DL; Speck RF; Goldsmith MA
    J Virol; 2001 Sep; 75(17):8063-73. PubMed ID: 11483751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sphingomyelinase restricts the lateral diffusion of CD4 and inhibits human immunodeficiency virus fusion.
    Finnegan CM; Rawat SS; Cho EH; Guiffre DL; Lockett S; Merrill AH; Blumenthal R
    J Virol; 2007 May; 81(10):5294-304. PubMed ID: 17344303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CCR5, CXCR4, and CD4 are clustered and closely apposed on microvilli of human macrophages and T cells.
    Singer II; Scott S; Kawka DW; Chin J; Daugherty BL; DeMartino JA; DiSalvo J; Gould SL; Lineberger JE; Malkowitz L; Miller MD; Mitnaul L; Siciliano SJ; Staruch MJ; Williams HR; Zweerink HJ; Springer MS
    J Virol; 2001 Apr; 75(8):3779-90. PubMed ID: 11264367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relative activity of "function sparing" HIV-1 entry inhibitors on viral entry and CCR5 internalization: is allosteric functional selectivity a valuable therapeutic property?
    Muniz-Medina VM; Jones S; Maglich JM; Galardi C; Hollingsworth RE; Kazmierski WM; Ferris RG; Edelstein MP; Chiswell KE; Kenakin TP
    Mol Pharmacol; 2009 Mar; 75(3):490-501. PubMed ID: 19064629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis, antiviral activity and resistance of a novel small molecule HIV-1 entry inhibitor.
    Curreli F; Haque K; Xie L; Qiu Q; Xu J; Yong W; Tong X; Debnath AK
    Bioorg Med Chem; 2015 Dec; 23(24):7618-28. PubMed ID: 26602829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The rise and fall of polyanionic inhibitors of the human immunodeficiency virus type 1.
    Pirrone V; Wigdahl B; Krebs FC
    Antiviral Res; 2011 Jun; 90(3):168-82. PubMed ID: 21439325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cenicriviroc, an orally active CCR5 antagonist for the potential treatment of HIV infection.
    Klibanov OM; Williams SH; Iler CA
    Curr Opin Investig Drugs; 2010 Aug; 11(8):940-50. PubMed ID: 20721836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of HIV-1 entry: multiple keys to close the door.
    Hertje M; Zhou M; Dietrich U
    ChemMedChem; 2010 Nov; 5(11):1825-35. PubMed ID: 20845361
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.